Yujin Hoshida

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

thelancet.com Favicon

futuremedicine.com Favicon

gastrojournal.org Favicon

Articles

The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial - Nature Communications

Mar 10, 2024 | nature.com | David Hsiehchen |Rolf A. Brekken |Amit Singal |Hao Yue Zhu |Yujin Hoshida |Courtney Katz

AbstractImmune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a single-arm phase 2 trial evaluating frontline bavituximab, a phosphatidylserine targeting antibody, plus pembrolizumab (anti-PD-1) in patients with unresectable hepatocellular carcinoma (NCT03519997).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →